Name: Interest Coverage

Definition: Interest coverage tells you how easily the company can pay interest on its debt using operating profits. It’s like asking: “Can the company comfortably make its loan payments, or is it barely scraping by?” The higher the ratio, the safer. A very low ratio means debt payments may strain the business, especially if profits drop.

Interpretation:
• In '2021', OCX's interest coverage was -251.97, indicating the firm's ability to meet its interest obligations. Industry average for Biotechnology: In Vitro & In Vivo Diagnostic Substances in '2021' stood at -3.73.
• In '2022', OCX's interest coverage was -223.24, indicating the firm's ability to meet its interest obligations. The increase since '2021' reflects strengthening financial performance. Industry average for Biotechnology: In Vitro & In Vivo Diagnostic Substances in '2022' stood at -1.40. Industry average increased by 2.32 compared to previous year.
• In '2023', OCX's interest coverage was -476.98, indicating the firm's ability to meet its interest obligations. The decline from '2022' may indicate some operational or financial challenges. Industry average for Biotechnology: In Vitro & In Vivo Diagnostic Substances in '2023' stood at -1.86. Industry average declined by 0.45 from previous year.
• In '2024', OCX's interest coverage was -721.18, indicating the firm's ability to meet its interest obligations. The decline from '2023' may indicate some operational or financial challenges. Industry average for Biotechnology: In Vitro & In Vivo Diagnostic Substances in '2024' stood at -1.28. Industry average increased by 0.57 compared to previous year.
Overall, OCX's interest coverage has been volatile but showed a downward trend over the past 4 years.

Formula: Interest Coverage = EBIT / Interest Expense

Good Range: Minimum 3-5 desirable; below 1 is risky.